About Us

Vision & Mission

We are passionate about improving health outcomes for individuals with GI disorders and autoimmune diseases.

We help clinicians to get their patients with complex diseases treated and in remission faster using precision-guided care.

LEADERSHIP TEAM

Mike- Walther

Mike Walther serves as our President. Prior to Prometheus, Mike was most recently General Manager of Aries Pharmaceuticals having joined in 2017 to help establish the startup capabilities, commercial strategy…

Read More

Thierry Dervieux, PharmD, PhD

Thierry Dervieux PharmD., PhD is our Chief Scientific Officer.  Prior to joining Prometheus, Thierry was Chief Scientific Officer at Exagen Diagnostics where he spent a decade building the Avise® portfolio of testing solutions to…

Read More

Patricia Vasquez

Patricia Vasquez is our Senior Vice President of Marketing and Corporate Development.  Patricia previously served as Vice President, Global Marketing, Business Development and Service for Inova Diagnostics, A Werfen Company, where she established technology…

Read More

Brian Littlefied

Brian Littlefield is the Senior Vice President of Information Services. Brian previously served at Exagen Diagnostics, where he established the IS function and led development and implementation of the…

Read More

James Garfield

James Garfield is our Vice President of Commercial Operations and Analytics.  James previously served as the Senior Director of Customer Success for Agendia, Inc., where he managed international customer service applications, pre-analytical and post-analytical workflows…

Read More
BOARD OF DIRECTORS

Mark McKenna

Mr. McKenna serves as President, CEO and member of the board of Prometheus Biosciences. Prior to joining Prometheus Biosciences, Mr. McKenna was President & CEO of Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies.

Read More

Jim Laur, JD

James Laur is Vice President, Intellectual Property and heads up Cedars-Sinai Technology Ventures reporting to the health system’s Chief Financial Officer. Mr. Laur’s primary responsibilities are focused on innovation, technology transfer and international business activities.

Read More

Martin Hendrix

Martin joined NHSc in 2012 with the task of building a healthcare M&A capability for the group. Since then he has kept a relentless passion for growing the company’s portfolio through creative deals, ranging from large M&A transactions to small licensing deals and everything in between.

Read More
Scientific Advisory Board

William Sandborn, MD

Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010…

Read More

Dermot McGovern, MD, PhD

Dr. McGovern is a gastroenterologist and preeminent geneticist in the IBD field. Dr. McGovern completed his GI fellowship and obtained a PhD in complex disease genetics at the University of Oxford, England before moving to Cedars-Sinai …

Read More

Diane Mould, PhD

Dr. Diane Mould has spent 30 years as a pharmacokineticist in the industry specializing in population pharmacokinetic / pharmacodynamic modeling. Dr. Mould is the founder of Baysient LLC, a company that develops systems to individualize doses of drugs that are difficult to manage…

Read More

Adam Cheifetz, MD

Adam S. Cheifetz is the Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective…

Read More